Structural basis of influenza virus neutralization.
Although seasonal influenza vaccines play a valuable role in reducing the spread of virus at the population level, ongoing viral evolution to evade immune responses remains problematic. No current vaccines elicit enduring protection in the face of emerging and re-emerging influenza viruses that are rapidly undergoing antigenic drift. Eliciting broadly cross-neutralizing antibody (nAb) responses against influenza virus is a crucial goal for seasonal and pandemic influenza vaccine preparation. Recent three-dimensional structure information obtained from crystallization of influenza antigens in complex with nAbs has provided a framework for interpreting antibody-based viral neutralization that should aid in the design of vaccine immunogens. Here, we will review current knowledge of the structure-based mechanisms contributing to the neutralization and neutralization escape of influenza viruses. We will also explore the potential for this structure-based approach to overcome the obstacles in developing the highly desired "universal" influenza vaccine.
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Thomas
T
Han
Wayne A
WA
Marasco
D000818:Animals; D057134:Antibodies, Neutralizing / Q000502:physiology*; D006801:Humans; D007252:Influenza Vaccines / Q000138:chemical synthesis / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D009500:Neutralization Tests / Q000379:methods / Q000639:trends; D009975:Orthomyxoviridae / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity*
D057134:Antibodies, Neutralizing; D007252:Influenza Vaccines
J Med Virol. 2000 May;61(1):94-9
10745239
Adv Virus Res. 1988;34:247-81
3046255
PLoS One. 2008;3(12):e3942
19079604
Arch Virol. 2003 Mar;148(3):469-86
12607099
Nat Struct Mol Biol. 2009 Mar;16(3):265-73
19234466
J Cell Biol. 1986 Jan;102(1):11-23
3753607
Pediatrics. 2006 Apr;117(4):e610-8
16585278
Cell. 1982 Dec;31(2 Pt 1):417-27
6186384
J Gen Virol. 1997 Oct;78 ( Pt 10):2441-6
9349462
Acta Virol. 1979 Jan;23(1):9-20
35964
J Virol. 2005 Mar;79(5):2814-22
15709000
PLoS One. 2009;4(3):e5079
19333374
J Comput Chem. 2004 Oct;25(13):1605-12
15264254
Virology. 1994 Nov 15;205(1):360-3
7975232
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):768-77
15299376
Science. 2009 Apr 10;324(5924):246-51
19251591
Cell. 1992 Feb 21;68(4):635-45
1739972
Virology. 2002 Mar 1;294(1):70-4
11886266
Science. 2004 Mar 19;303(5665):1866-70
14764887
Virus Res. 1997 Jun;49(2):173-86
9213392
Acta Virol. 1999 Aug;43(4):237-44
10749369
Vaccine. 2003 May 1;21(16):1776-9
12686093
Infect Immun. 1982 Sep;37(3):912-8
6182104
Cell. 1987 Aug 28;50(5):665-6
3304656
J Virol. 1968 Apr;2(4):281-8
4911843
Virology. 1987 Aug;159(2):288-98
3617501
Drugs Aging. 2005;22(6):495-515
15974640
Nature. 1981 Jan 29;289(5796):373-8
6162101
FEBS Lett. 1980 Dec 29;122(2):283-7
7202720
N Engl J Med. 1972 Jun 22;286(25):1329-32
5027388
N Engl J Med. 2004 Jan 15;350(3):218-20
14724300
J Gen Virol. 1996 Jul;77 ( Pt 7):1483-7
8757990
Virology. 1975 Dec;68(2):440-54
128196
Cell. 1993 May 21;73(4):823-32
8500173
APMIS. 1999 Mar;107(3):289-96
10223301
Virology. 2004 Aug 1;325(2):287-96
15246268
Science. 2004 Mar 19;303(5665):1838-42
14764886
mBio. 2010 May 18;1(1):
20689752
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8967-72
10430879
PLoS Pathog. 2010 Feb 26;6(2):e1000796
20195520
Nature. 2009 Feb 19;457(7232):1012-4
19020500
Nat Struct Biol. 1998 Feb;5(2):119-23
9461077
Proteins. 2000 Sep 1;40(4):572-8
10899782
Virology. 1975 Dec;68(2):426-39
173078
J Virol. 2008 May;82(10):4834-43
18321971
Trends Microbiol. 1994 Feb;2(2):39-43
8162439
Nature. 1994 Sep 1;371(6492):37-43
8072525
Vaccine. 2007 Sep 28;25(39-40):6852-62
17719149
J Infect Dis. 1974 Apr;129(4):411-20
4593871
Clin Diagn Lab Immunol. 1996 Sep;3(5):511-6
8877127
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91
18413603
Mayo Clin Proc. 2010 Mar;85(3):257-73
20118381
Virology. 1988 May;164(1):230-7
2452514
Vaccine. 1998 Nov;16(19):1780-7
9795381
J Clin Invest. 2010 May;120(5):1663-73
20389023
J Virol. 1993 May;67(5):2552-8
7682624
Annu Rev Immunol. 1990;8:737-71
2188678
Virology. 1981 Sep;113(2):725-35
7023022
Virology. 2008 Jan 20;370(2):403-14
17936324
J Virol. 1994 Jan;68(1):517-20
8254764
Annu Rev Biochem. 2000;69:531-69
10966468
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2706-11
14981267
Virology. 1983 Apr 15;126(1):106-16
6189287
Nat Struct Biol. 1999 Jun;6(6):530-4
10360354
Virology. 2003 May 10;309(2):209-18
12758169
J Gen Virol. 2001 Oct;82(Pt 10):2475-2484
11562540
Nature. 1995 Jul 6;376(6535):92-4
7596443
Virology. 1978 Jun 1;87(1):13-20
664248
J Biol Chem. 1992 Jul 5;267(19):13573-9
1618859
Virology. 1993 Jun;194(2):781-8
7684877
Nature. 2006 Nov 16;444(7117):378-82
17108965
Vaccine. 2002 Dec 20;20 Suppl 5:B40-4
12477418
Virology. 2002 Oct 25;302(2):294-8
12441073
Nat Med. 2010 Feb;16(2):224-7
20081864
EMBO J. 2002 Mar 1;21(5):865-75
11867515
J Cell Biol. 1986 Oct;103(4):1179-91
2429970
Arch Virol. 1990;114(1-2):1-26
1699509
Bull Hist Med. 2002 Spring;76(1):105-15
11875246
Am J Epidemiol. 2009 Sep 1;170(5):650-6
19625341
Nature. 1984 Oct 18-24;311(5987):678-80
6207440
Nature. 2008 Jun 26;453(7199):1258-61
18480754